Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors
Li Zhu(University of Pittsburgh), Adrian V. Lee(Baylor College of Medicine), Leisha A. Emens(Johns Hopkins University), Sarah Sammons(Dana-Farber Cancer Institute), Carey K. Anders(Duke University), Priscilla K. Brastianos(Massachusetts General Hospital), George C. Tseng(University of Pittsburgh), Naema Nayyar(Massachusetts General Hospital), Jessica L. Narloch(Cancer Institute (WIA)), Ugonma Chukwueke, Sayali Onkar(University of Pittsburgh), Peter C. Lucas(University of Pittsburgh), Catherine Luedke(Duke Medical Center), Rim Kim(NSABP Foundation), Adam C. Soloff(University of Pittsburgh), Katherine L. Pogue–Geile(NSABP Foundation), Allison Hall(Duke Medical Center), Marion Joy(UPMC Hillman Cancer Center), Dario A.A. Vignali(University of Pittsburgh), Kimberly Blackwell(Duke University), Steffi Oesterreich(University of Pittsburgh)
Cited by 15
Related Papers
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960